Further refinement revealed caveolin-1 and Sox-2 protein measurements to retain high predictive accuracy for cetuximab response prediction, which we confirmed in patient samples using immunohistochemistry of a TMA from cetuximab-treated patients with HNSCC with known clinical responses. The gene discussed is CAV1; the disease is head and neck squamous cell carcinoma.